多种血浆生物标志物与糖尿病肾病进展的关联:CRIC研究
该病例队列研究纳入894例糖尿病且eGFR<60 ml/min/1.73 m2的CRIC参与者,检测KIM-1、TNFR-1、TNFR-2、MCP-1、suPAR和YKL-40等血浆标志物,发现较高浓度均与糖尿病肾病进展风险增加相关,校正竞争标志物后TNFR-2风险最高。
要点
- 多种血浆标志物(KIM-1、TNFR-1/2、MCP-1、suPAR、YKL-40)升高与糖尿病肾病进展风险增加相关。
- 校正其他标志物后,KIM-1、TNFR-2和YKL-40仍与进展相关,TNFR-2风险最高。
- KIM-1、TNFR-1、TNFR-2和YKL-40与eGFR下降速率相关。
核心结论
- 较高血浆KIM-1、TNFR-1、TNFR-2、MCP-1、suPAR和YKL-40水平与糖尿病肾病进展风险增加相关。
- 校正其他生物标志物后,TNFR-2与糖尿病肾病进展的关联风险最高(校正HR 1.61,95%CI 1.15-2.26)。
研究设计与样本
- 病例队列研究,纳入894例糖尿病且基线eGFR<60 ml/min/1.73 m2的CRIC研究参与者。
- 中位随访8.7年,病例为发生糖尿病肾病进展(ESKD或eGFR下降40%)的患者。
主要发现
- 较高浓度的KIM-1、TNFR-1、TNFR-2、MCP-1、suPAR和YKL-40均与糖尿病肾病进展风险增加相关,即使校正已确立的临床危险因素后仍显著。
- 校正竞争生物标志物后,KIM-1、TNFR-2和YKL-40仍与糖尿病肾病进展相关,其中TNFR-2风险最高(校正HR 1.61,95%CI 1.15-2.26)。
- KIM-1、TNFR-1、TNFR-2和YKL-40与eGFR下降速率相关。
临床怎么用
- 血浆TNFR-2、KIM-1和YKL-40等标志物可能有助于识别糖尿病肾病进展高危患者。
- suPAR和YKL-40作为血浆生物标志物的影响需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although diabetic kidney disease is the leading cause of ESKD in the United States, identifying those patients who progress to ESKD is difficult. Efforts are under way to determine if plasma biomarkers can help identify these high-risk individuals. METHODS: In our case-cohort study of 894 Chronic Renal Insufficiency Cohort Study participants with diabetes and an eGFR of <60 ml/min per 1.73 m2 at baseline, participants were randomly selected for the subcohort; cases were those patients who developed progressive diabetic kidney disease (ESKD or 40% eGFR decline). Using a multiplex system, we assayed plasma biomarkers related to tubular injury, inflammation, and fibrosis (KIM-1, TNFR-1, TNFR-2, MCP-1, suPAR, and YKL-40). Weighted Cox regression models related biomarkers to progression of diabetic kidney disease, and mixed-effects models estimated biomarker relationships with rate of eGFR change. RESULTS: Median follow-up was 8.7 years. Higher concentrations of KIM-1, TNFR-1, TNFR-2, MCP-1, suPAR, and YKL-40 were each associated with a greater risk of progression of diabetic kidney disease, even after adjustment for established clinical risk factors. After accounting for competing biomarkers, KIM-1, TNFR-2, and YKL-40 remained associated with progression of diabetic kidney disease; TNFR-2 had the highest risk (adjusted hazard ratio, 1.61; 95% CI, 1.15 to 2.26). KIM-1, TNFR-1, TNFR-2, and YKL-40 were associated with rate of eGFR decline. CONCLUSIONS: Higher plasma levels of KIM-1, TNFR-1, TNFR-2, MCP-1, suPAR, and YKL-40 were associated with increased risk of progression of diabetic kidney disease; TNFR-2 had the highest risk after accounting for the other biomarkers. These findings validate previous literature on TNFR-1, TNFR-2, and KIM-1 in patients with prevalent CKD and provide new insights into the influence of suPAR and YKL-40 as plasma biomarkers that require validation.
引用
- Schrauben SJ, Shou H, Zhang X, et al. Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2020. PMID: 33122288. doi:10.1681/ASN.2020040487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。